14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
NRIX vs ANNX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Nurix Therapeutics, Inc. (NRIX) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NRIX carries a Unified Composite Score of 50.1/100 (HOLD) at $14.24 (N/M Forward P/E, 41.3% operating margin), whereas ANNX carries 43.5/100 (HOLD) at $3.48 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: NRIX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.2); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NRIX vs ANNX. Trailing 12-month operating profitability (NRIX 41.3% vs ANNX 0.0%) and valuation multiples (NRIX N/M vs ANNX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $747.8M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ NRIX vs ANNX Key Questions & Quantitative Answers
As of Nov 17, 2026, Nurix Therapeutics, Inc. (NRIX) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NRIX carries a Unified Composite Score of 50.1/100 (HOLD) at $14.24 (N/M Forward P/E, 41.3% operating margin), whereas ANNX carries 43.5/100 (HOLD) at $3.48 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: NRIX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.2); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NRIX leads the Growth & Scale pillar: NRIX posts +8426.3% YoY revenue growth and +0.0% YoY earnings growth on $702M TTM revenue (52.4% gross margin, 41.3% operating margin), compared with ANNX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, NRIX generates $702M in USD-normalized revenue versus N/A for ANNX. In operating R&D and SG&A reinvestment, NRIX deploys 11.1% of Rev ($78M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANNX.
NRIX screens cheaper on headline valuation multiples. NRIX trades at N/M Forward P/E, 6.4x Trailing P/E, N/M PEG, and 1.5x EV/Revenue (52.7% FCF margin), whereas ANNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NRIX (44.0% ROE) versus ANNX (-130.8% ROE) capital efficiency.
In options market volatility and institutional positioning, NRIX carries 79.3% implied volatility (4th %ile, Compressed (<25th %ile)), a 2.92x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.98β · 138% Vol realized risk). By comparison, ANNX carries 569.3% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.69β · 63% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.